Removal of Ovaries Decreases Cancer Risk for Women at High-Risk

	Tweet

Women with mutations in the BRCA1 or BRCA2 genes can significantly reduce their risk of certain types of cancer by having their ovaries removed, according to a study in the July 12 issue of JAMA.

Women with a harmful mutation in the BRCA1 or BRCA2 gene have a high lifetime risk of ovarian cancer (range, 15 percent-54 percent), and mutations in either of these genes increase susceptibility to cancers of the ovary, fallopian tube, and peritoneum (abdominal lining), according to background information in the article. Women with this mutation are often advised to undergo preventive oophorectomy (surgical removal of the ovaries). The effectiveness of this intervention has not been prospectively evaluated in a large group of patients.

Steven A. Narod, M.D., of the Toronto-Sunnybrook Regional Cancer Center, Toronto, Ontario, and colleagues conducted a study to determine the absolute risks for developing ovarian, fallopian tube, and peritoneal cancers in a group of BRCA1 and BRCA2 mutation carriers and estimated the risk reduction associated with salpingo-oophorectomy (surgical removal of the ovaries and fallopian tubes).

Women known to carry a BRCA1 or BRCA2 mutation were identified from an international registry between 1992 and 2003. A total of 1,828 carriers at 1 of 32 centers in Canada, the United States, Europe, and Israel completed questionnaires at baseline and follow-up. Participants were observed from the date of study entry until: diagnosis of ovarian, fallopian tube, or peritoneal cancer; death; or the date of the most recent follow-up.

After an average follow-up of 3.5 years, 50 new ovarian, fallopian tube, and peritoneal cancer cases were reported in the group. Of the 1,828 women, 555 (30 percent) underwent preventive removal of the ovaries and tubes prior to study entry, 490 (27 percent) underwent the procedure after entering the study, and 783 (43 percent) did not undergo the procedure. There were 32 new cancers diagnosed in women with intact ovaries.

The estimated cumulative incidence of peritoneal cancer is 4.3 percent at 20 years after oophorectomy. The overall (adjusted) reduction in cancer risk associated with bilateral oophorectomy is 80 percent. The researchers estimated the risk of ovarian cancer to be 62 percent for BRCA1 carriers and 18 percent for BRCA2 carriers in women up to age 75 with both ovaries intact.

“Women who carry a mutation in the BRCA1 gene are asked to consider prophylactic bilateral salpingo-oophorectomy at age 35 or thereabouts, in order to reduce the risk of ovarian, fallopian tube, and breast cancer. Our observations support this recommendation. It may be reasonable to wait until a time closer to menopause to prevent ovarian and fallopian tube cancer in BRCA2 carriers but this delay will diminish the level of protection offered against breast cancer in this subgroup,” the authors write.

“We estimate the magnitude of the risk reduction [from preventive removal of the ovaries and tubes] to be approximately 80 percent and the residual risk of 4 percent of peritoneal cancer is not sufficiently high to recommend against the procedure.

It is important that both the fallopian tubes and ovaries be removed because either site may be the origin of cancer and both organs should be examined in fine detail to rule out the presence of microscopic disease,” the researchers conclude.

American Medical Association (AMA)

RELATED STORIES:
Faulty proteins may prove significant in identifying new treatments for ovarian cancer   Optimistic women with ovarian cancer fare better   Ovarian Cancer Screening Not Catching Early Disease   Wayne State proves targeted tumor freezing therapy increases ovarian cancer survival   Family breast cancer history ups ovarian cancer risk   Proteins show promise for ovarian cancer screening   Women often opt to surgically remove their breasts, ovaries to reduce cancer risk   New platinum-phosphate compounds kill ovarian cancer cells   Young early stage ovarian cancer patients can preserve fertility   Vaccine/Antibody Therapy Effective in Melanoma and Ovarian Cancer   DNA repair pathway score for predicting chemotherapy response in ovarian cancer patients   Symptom screening plus a simple blood test improves early detection of ovarian cancer   Team effort to beat ovarian cancer   Project Achilles Pinpoints Vulnerabilities in Ovarian Cancer   Study Finds Aspirin, Vitamin E Don’t Prevent Cancer   Low-dose Pill reduces ovarian cancer risk   Researchers Identify Genes Tied to Deadliest Ovarian Cancers   Protein in urine may point to more sensitive screening tests for women with ovarian cancer   Two gene mutations mark deadly ovarian cancer   ‘Clumping’ Protein Linked to Return of Ovarian Cancer   Soy may lessen risk of endometrial, ovarian cancers   UBC discovery may lead to ‘smart’ therapies for breast, ovarian cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]